Industry News

Pharmaceutical Industry News

GSK showed a “totally…

September 24th, 2026|Fierce Pharma|

GSK showed a “totally unacceptable” lack of transparency in its interactions with the PMCPA, the U.K. self-regulatory body ruled.

Boehringer Ingelheim is bidding…

September 24th, 2026|Fierce Pharma|

Boehringer Ingelheim is bidding adieu to its biologics contract manufacturing unit in China, inking a small-scale deal that gives local developer Raas Blood Products an established biologics production base for its lead antibody drug candidate.

The FDA has green-lighted…

September 24th, 2026|Fierce Pharma|

The FDA has green-lighted Elevar’s FGFR2-selective inhibitor Lyrfigtu in bile duct cancer, making it the first novel cancer drug from a Korean company to secure FDA approval.